Baseline characteristics for GARNET cohort (before matching) and for overall and treatment-specific real-world cohorts
| GARNET (dostarlimab) cohort (n=153) | Real-world cohort | ||||||
| Overall (n=999) | Paclitaxel monotherapy (n=116) | Carboplatin +paclitaxel (n=279) | Carboplatin+ liposomal doxorubicin (n=141) | Liposomal doxorubicin monotherapy (n=130) | Carboplatin monotherapy (n=93) | ||
| Race, n (%) | * | * | * | ||||
| White | 117 (76.5) | 841 (84.2) | 87 (75.0) | 242 (86.7) | 119 (84.4) | 112 (86.2) | 86 (92.5) |
| Black | 5 (3.3) | 57 (5.7) | 10 (8.6) | 18 (6.5) | 6 (4.3) | 4 (3.1) | 3 (3.2) |
| Other | 8 (5.2) | 78 (7.8) | 18 (15.5) | 17 (6.1) | 12 (8.5) | 7 (5.4) | 3 (3.2) |
| Unknown | 23 (15.0) | 23 (2.3) | 1 (0.9) | 2 (0.7) | 4 (2.8) | 7 (5.4) | 1 (1.1) |
| Age (years) | |||||||
| Median (range) | 65 (39–85) | 66 (36–85) | 66 (36–82) | 67 (37–84) | 67 (42–84) | 68 (37–85) | 70 (37–83) |
| <65, n (%) | 75 (49.0) | 428 (42.8) | 52 (44.8) | 110 (39.4) | 59 (41.8) | 43 (33.1) | 29 (31.2) |
| ≥65, n (%) | 78 (51.0) | 571 (57.2) | 64 (55.2) | 169 (60.6) | 82 (58.2) | 87 (66.9) | 64 (68.8) |
| ECOG PS†, n (%) | * | * | * | * | * | * | |
| 0 | 61 (39.9) | 320 (32.0) | 41 (35.3) | 97 (34.8) | 45 (31.9) | 37 (28.5) | 30 (32.3) |
| 1 | 92 (60.1) | 181 (18.1) | 21 (18.1) | 44 (15.8) | 35 (24.8) | 23 (17.7) | 14 (15.1) |
| Unknown | 0 | 498 (49.8) | 54 (46.6) | 138 (49.5) | 61 (43.3) | 70 (53.8) | 49 (52.7) |
| Histology‡, n (%) | * | * | * | * | * | * | |
| Endometrioid | 121 (79.1) | 424 (42.4) | 47 (40.5) | 117 (41.9) | 55 (39.0) | 58 (44.6) | 35 (37.6) |
| Non-endometrioid | 30 (19.6) | 575 (57.6) | 69 (59.5) | 162 (58.1) | 86 (61.0) | 72 (55.4) | 58 (62.4) |
| Unknown | 2 (1.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| FIGO stage‡, n (%) | * | * | |||||
| I/II | 65 (42.5) | 221 (22.1) | 33 (28.4) | 44 (15.8) | 31 (22.0) | 46 (35.4) | 19 (20.4) |
| III/IV | 88 (57.5) | 778 (77.9) | 83 (71.6) | 235 (84.2) | 110 (78.0) | 84 (64.6) | 74 (79.6) |
| Tumor grade‡, n (%) | * | * | * | * | * | * | |
| 1/2 | 102 (66.7) | 274 (27.4) | 26 (22.4) | 79 (28.3) | 32 (22.7) | 34 (26.2) | 27 (29.0) |
| 3/4 | 46 (30.1) | 389 (38.9) | 48 (41.4) | 112 (40.1) | 54 (38.3) | 54 (41.5) | 30 (32.3) |
| Unknown | 5 (3.3) | 336 (33.6) | 42 (36.2) | 88 (31.5) | 55 (39.0) | 42 (32.3) | 36 (38.7) |
| Number of prior platinum-based therapies§, n (%) | * | * | * | * | * | * | |
| 0 | 2 (1.3)¶ | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 128 (83.7) | 999 (100) | 116 (100) | 279 (100) | 141 (100) | 130 (100) | 93 (100) |
| 2+ | 23 (15.0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Surgery, n (%) | |||||||
| Yes | 135 (88.2) | 815 (81.6) | 97 (83.6) | 244 (87.5) | 117 (83.0) | 98 (75.4) | 77 (82.8) |
| No | 18 (11.8) | 184 (18.4) | 19 (16.4) | 35 (12.5) | 24 (17.0) | 32 (24.6) | 16 (17.2) |
*P<0.0001: differences in baseline characteristics between cohorts were measured using the Chi-squared test; if at least one cell was ≤5, then Fisher’s exact test was used.
†status at index.
‡at initial diagnosis.
§in the recurrent/advanced setting.
¶the prior therapies that these patients received were not counted as a line of therapy per trial protocol; these patients were excluded from this analysis.
ECOG PS, Eastern Cooperative Oncology Group Performance Status; FIGO, International Federation of Gynecology and Obstetrics.